Bladder Cancer Prognosis Programme (BCPP)

The Bladder Cancer Prognosis Programme (BCPP) recruited over 1300 bladder cancer patients between 2005 and 2011. The biospecimen collection, comprising fresh-frozen bladder cancer tissues as well as blood and urine, has grown to be one of the world’s largest and most detailed providing a unique resource for a wide array of bladder cancer studies. Each biological sample is linked to over one thousand variables containing clinical, epidemiological and pathological data. All samples have also been linked to follow up data on recurrence and progression.

The following sub-projects have been delivered using BCPP data or samples

• Assessing the effect of lifestyle factors on bladder cancer pathology and on the recurrence and progression of this disease.
• The quality of life of bladder cancer patients
• A Randomized Clinical Trial to assess the effect of selenium and vitamin E supplementation on the risk of recurrence and progression in patients with bladder cancer
• The development of a prediction model for recurrence and progression of bladder cancer using proteomic, genomic and epigenomic biomarker panels
• The development of a non-invasive (urine) test for the diagnosis and risk stratification of bladder cancer

Our objectives are as follows:

• To assess the effect of lifestyle factors (such as smoking, dietary habits, fluid intake and environmental exposures) on the recurrence and progression of bladder cancer.
• To study health related quality of life and its association with recurrence and progression of bladder cancer.
• To establish a bladder cancer biospecimen collection (that will comprise blood, urine, and bladder tissue).
• To study the predictive effect of molecular markers on the recurrence and progression of bladder cancer.
• To investigate whether selenium and/or vitamin E supplementation reduces the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer.

Cumulative accural - December 2011

This graph shows the cumulative recruitment at each hospital (site) over the course of the BCPP recruitment period.

Accrual data - December 2011

This pie chart shows the proportion of patients recruited to the BCPP study from the pool of potential participants across the West Midlands region.

Sample collection data

This graph shows the percentage of patients that donated blood, tissue and urine samples that form the basis of epidemiological and pathological studies of bladder cancer.

Study Management Group

• Professor Rik Bryan, Chief Investigator
• Professor Maurice Zeegers (Maastricht University)
• Professor KK Cheng (University of Birmingham)
• Professor Nick James (The Institute of Cancer Research)

Support Team

• Mr Ben Abbotts, Trial Coordinator
• Ms Naheema Gordon, Laboratory Technician
• Dr Roland Arnold, Bioinformatician
• Dr Anshita Goel, Bioinformatician
• Dr Ben Tura, Data Scientist
• Mr Keval Patel, Consultant Urological Surgeon
• Miss Nada Humayun-Zakaria, NIHR Academic Clinical Lecturer in Urology

Co-investigator Team

• Professor Cindy Billingham, Professor of Biostatistics
• Dr Douglas Ward, Senior Research Fellow (Translational Medicine)
• Ms Sarah Pirrie, Trial Statistician

External Collaborators since 2005

• Professor John Kelly, UCL
• Professor Margaret Knowles, University of Leeds
• Professor Hardev Pandha, University of Surrey
• Professor Anne Kiltie, University of Oxford
• Professor Bart Kiemeney, Radboud University Nijmegen Medical Centre, The Netherlands
• Professor Chris Probert, University of Liverpool
• Dr Claire Perks, University of Bristol
• Dr Stuart Savill, Betsi Cadwaladr University Health Board
• Mr Rakesh Heer, Northern Institute for Cancer Research
• Dr Sascha Ott, University of Warwick
• Dr Martin Lord, Uppsala University, Sweden
• Professor Kam Chana, University of Oxford
• Nonacus Limited, Birmingham UK

• Study protocol
• The Bladder Cancer Webcafé
• Cancer Research UK
• Action Bladder Cancer UK
• The SELENIB Trial

For any enquiries about our research group, you can contact us via the following methods:

Postal address:

BCPP Office
Department of Cancer and Genomic Sciences
G34, Robert Aitken Building
University of Birmingham
Vincent Drive
Edgbaston
Birmingham
B15 2TT

E-mail:

bcpp@trials.bham.ac.uk

Telephone:

0121 415 8836